Vice President & Head of Vaccines and Microbiome, Global Regulatory Affairs, Janssen
As part of its worldwide microbiome series, Global Engage is pleased to announce the Microbiome R&D and Business Collaboration Forum: Europe which will be held on 3 – 4 April, 2017.
The forum is moving from London to Amsterdam!
And not only is the venue changing, the agenda is also being transformed.
The 2017 Microbiome R&D and Business Collaboration Forum: Europe will feature extended panel discussions and round table debates. Plus, there will be venture capital pitch and partner sessions where you can source that all important financing to transform your research into a viable product. With over 60 talks and 7 hours dedicated to networking.
Recognised around the world, as the leading conferences for bringing together Pharma, Biotech, Academic Institutions and investors who are partnering together to develop and progress ground-breaking microbiome research into commercially viable products. The 2017 Forum is not one to miss.
Associate Professor, Luxembourg Centre for Systems Biomedicine, University of Luxembourg
Attracting over 300 attendees, the 11th meeting in the global series will build upon the success of last year’s highly acclaimed European meeting as well as our popular American and Asia forums to explore the interface between our evolving cultures, technologies and our microbiome through a series of interactive presentations and panel discussions with leading academics and industry experts as well as venture capital investors and leading solution, service and technology providers. The Global Engage series is rapidly gaining a fantastic reputation for fostering partnerships across academia, pharma and biotech. If looking to either learn more from the top scientists in the microbiome space; showcase exciting developments in your research; or seek partnerships and funding within the industry; it is an event not to be missed.
Roundtables in IBD, immuno-oncology, prebiotics
What makes commercial sense from both the pharma and patient perspective? We will discuss bringing drugs to market, regulation, quality control, and intellectual property within the microbiome space as well as investment models, current market opportunities and plenty of networking time.